AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONS
2. ORCL
3. ASML
4. BSX
5. ODFL
6. USO
7. LAD
8. SPIR
9. ROIV
10. CRCL

Go back to AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis
AbbVie (NYSE: ABBV) Delayed: 256.46 --0 (-0%)
Previous Close $256.46    52 Week High $68.12 
Open $256.46    52 Week Low $50.71 
Day High $256.46    P/E 55.63 
Day Low $256.46    EPS $4.61 
Volume 4,999